Search hospitals > Montana > Billings
Saint Vincent Healthcare
Claim this profileBillings, Montana 59101
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
264 reported clinical trials
9 medical researchers
Summary
Saint Vincent Healthcare is a medical facility located in Billings, Montana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Saint Vincent Healthcare is involved with conducting 264 clinical trials across 412 conditions. There are 9 research doctors associated with this hospital, such as Nicholas DiBella, Patrick Cobb, MD, Benjamin J. George, and Marwan Massouh.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
103 reported clinical trials
193 drugs studied
Patrick Cobb, MDSt. Vincent Frontier Cancer Center5 years of reported clinical research
Studies Breast Cancer
Studies Tumors
20 reported clinical trials
42 drugs studied
Benjamin J. GeorgeSCL Health Good Samaritan Medical Center Cancer Centers of Colorado5 years of reported clinical research
Studies Lymphoma
Studies Stomach Cancer
12 reported clinical trials
48 drugs studied
Marwan MassouhSaint James Community Hospital and Cancer Treatment Center6 years of reported clinical research
Studies Cancer
Studies Lung Cancer
11 reported clinical trials
35 drugs studied
Clinical Trials running at Saint Vincent Healthcare
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Cancer
Cancer
Ovarian Cancer
Fallopian Tube Cancer
Squamous Cell Carcinoma
Laryngeal Cancer
Peritoneal Cancer
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Marker-Directed Monitoring
for Breast Cancer
This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Vincent Healthcare?
Saint Vincent Healthcare is a medical facility located in Billings, Montana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Saint Vincent Healthcare is involved with conducting 264 clinical trials across 412 conditions. There are 9 research doctors associated with this hospital, such as Nicholas DiBella, Patrick Cobb, MD, Benjamin J. George, and Marwan Massouh.